Abstract
Recent evidence indicates that glucocorticoids (GCs) suppress bladder cancer cell invasion through the GC receptor (GR) pathway, whereas androgen-mediated androgen receptor (AR) signals induce bladder tumor progression. In this study, we assessed the effects of 2-(4-acetoxyphenyl)-2-chloro-N-methyl-ethylammonium chloride (compound A [CpdA]), which was shown to function as not only a GR modulator but also an AR antagonist, on the growth of bladder cancer. In GR/AR-positive cells, CpdA strongly inhibited cell proliferation and colony formation as well as increased G1 phase-arrested cell population and apoptosis. Specifically, CpdA at 1μM decreased cell viability of TCCSUP/UMUC3-control-short hairpin RNA (shRNA), TCCSUP/UMUC3-GR-shRNA, and TCCSUP/UMUC3-AR-shRNA by 50%/67%, 25%/26%, and 38%/58%, respectively. CpdA also inhibited cell migration and invasion of GR/AR-positive (up to 61% decrease) and GR-positive/AR-silencing (up to 51% decrease) lines and, less strongly, those of GR-silencing/AR-positive lines (up to 35% decrease). Additionally, in UMUC3-control xenograft-bearing male mice, CpdA more strongly suppressed tumor growth than dexamethasone or hydroxyflutamide. In reporter gene assays, CpdA failed to induce GR transactivat...Continue Reading
References
May 13, 1988·Science·R M Evans
Jun 27, 1997·The Journal of Biological Chemistry·H A KesterB van der Burg
Apr 28, 1999·Endocrinology·A Louw, P Swart
Nov 22, 2001·Journal of the National Cancer Institute·K NishimuraA Okuyama
May 17, 2002·The Journal of Biological Chemistry·David MasielloSteven P Balk
Mar 15, 2003·The Journal of Biological Chemistry·Duncan M GascoyneMaria d M Vivanco
Apr 23, 2003·Molecular and Cellular Endocrinology·T M TannerF Claessens
Aug 16, 2003·Endocrine Reviews·Karolien De BosscherGuy Haegeman
May 3, 2005·Steroids·Junguo Zhou, John A Cidlowski
Oct 26, 2005·Proceedings of the National Academy of Sciences of the United States of America·Karolien De BosscherGuy Haegeman
Jan 17, 2007·Cancer Biology & Therapy·Chengwen ZhangIngrid Herr
Apr 5, 2007·Journal of the National Cancer Institute·Hiroshi MiyamotoChawnshang Chang
Jul 17, 2007·Molecular and Cellular Endocrinology·Heike SchäckeKhusru Asadullah
Apr 25, 2008·BMC Urology·Aimee M JohnsonJay E Reeder
Jun 19, 2008·Cancer Research·Alexander YemelyanovIrina Budunova
Apr 3, 2009·Biochimica Et Biophysica Acta·Yi-Hua QianJan Xu
Jul 2, 2009·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Emira Ayroldi, Carlo Riccardi
Sep 25, 2009·Endocrine-related Cancer·Yu-Xia ChenJian Lu
Jan 20, 2010·Urology·Ji-Tao WuShu-Jie Xia
May 24, 2011·The Journal of Endocrinology·George SchlossmacherAnne White
May 27, 2011·Endocrine-related Cancer·Yichun ZhengHiroshi Miyamoto
Sep 29, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Ethan BaschUNKNOWN American Society of Clinical Oncology
Nov 25, 2011·Current Cancer Drug Targets·H MiyamotoK Izumi
Jan 10, 2012·BJU International·Hiroshi MiyamotoShuyuan Yeh
May 18, 2012·Japanese Journal of Clinical Oncology·Yi LiHiroshi Miyamoto
Jul 10, 2012·The Journal of Biological Chemistry·Moammir H AzizCarl G Maki
Aug 28, 2012·International Journal of Oncology·Koji IzumiHiroshi Miyamoto
Sep 27, 2012·Proceedings of the National Academy of Sciences of the United States of America·Jonathan B OverdevestDan Theodorescu
Oct 4, 2012·Molecular Cancer Therapeutics·Yichun ZhengHiroshi Miyamoto
Dec 27, 2012·Molecular and Cellular Endocrinology·Dariusz RatmanKarolien De Bosscher
Dec 29, 2012·PloS One·Haiyan GeChunxue Bai
Mar 1, 2013·Endocrine-related Cancer·Yi LiHiroshi Miyamoto
Mar 26, 2014·Cancer Letters·Yifeng JingShujie Xia
Apr 29, 2014·Molecular Endocrinology·Rucha PatelCarolyn L Cummins
Jun 2, 2014·Cancer Chemotherapy and Pharmacology·Hitoshi IshiguroHiroshi Miyamoto
Jul 13, 2014·American Journal of Clinical Pathology·Hitoshi IshiguroHiroshi Miyamoto
Feb 2, 2015·Oncotarget·Takashi KawaharaHiroshi Miyamoto
Citations
Feb 13, 2016·The Prostate·Takashi KawaharaHiroshi Miyamoto
Jan 16, 2016·Disease Markers·Hiroki Ide, Hiroshi Miyamoto
Jul 9, 2016·European Journal of Pharmacology·Adnan Dibas, Thomas Yorio
Oct 22, 2016·Cancer Biology & Therapy·Eiji KashiwagiHiroshi Miyamoto
Jan 10, 2017·Expert Opinion on Therapeutic Targets·Taichi MizushimaHiroshi Miyamoto
Jun 28, 2017·Molecular and Cellular Endocrinology·Satoshi InoueHiroshi Miyamoto
May 9, 2018·PloS One·Dorien ClarisseKarolien De Bosscher
Mar 1, 2018·BMC Cancer·Rochanawan SootichoteChanitra Thuwajit
Jun 21, 2016·Oncotarget·Eiji KashiwagiHiroshi Miyamoto
Jul 23, 2016·Oncotarget·Takashi KawaharaHiroshi Miyamoto
Oct 8, 2016·Oncoscience·Nora SundahlIlse M Beck
Aug 28, 2020·Frontiers in Oncology·Congcong XuYichun Zheng
Nov 15, 2017·British Journal of Cancer·Peng LiHiroshi Miyamoto
Mar 1, 2017·Cancers·Peng LiHiroshi Miyamoto
Dec 7, 2018·Cancers·Hiroki IdeHiroshi Miyamoto
Sep 20, 2019·Molecular Carcinogenesis·Hiroki IdeHiroshi Miyamoto
Aug 8, 2020·Cancers·Hiroki Ide, Hiroshi Miyamoto
Mar 30, 2018·Molecular Cancer Therapeutics·Satoshi InoueHiroshi Miyamoto